Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

by Chia‐Hsun Chu, Tzu‐Hsuan Chiu, Chin‐Chou Wang, Wen‐Chen Chang, Allen Chung‐Cheng Huang, Chien‐Ying Liu, Chih‐Liang Wang, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi S. Kuo, Cheng‐Ta Yang
Published 2020-06-01

Phimosis: A rare complication of immunotherapy with durvalumab

by Luis Gabriel Vázquez-Lavista, Luis Llorente, Jorge Alatorre-Alexander, José Arturo Ramírez-Muciño
Published 2020-11-01

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy

by Emma Sanderson, Hari Wimaleswaran, Clare Senko, Shane White, Christine F. McDonald
Published 2020-04-01

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

by Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X
Published 2018-07-01

Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature

by N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, V. V. Breder, T. N. Borisova, D. I. Yudin, M. S. Ardzinba, A. V. Egorova, A. A. Fedorova
Published 2019-06-01

Trial watch: Immune checkpoint blockers for cancer therapy

by Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Published 2017-11-01

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

by Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A
Published 2018-01-01

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

by Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD
Published 2021-07-01

Retinal Vasculitis Secondary to Durvalumab

by Antonio R. Andrade, Aina Moll-Udina, Ruth Martin, Esther Cilveti, Olaia Subirà, Laura Disfetano, Jose García-Arumí
Published 2020-05-01

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

by Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Published 2018-12-01

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

by Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Published 2019-01-01

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer

by Eun Young Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Hee Young Lee, Jeong Ho Kim
Published 2019-04-01

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

by Ryosuke Imai, Sumie Ikemura, Torahiko Jinta
Published 2021-04-01

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

by Pierluigi Bonomo, Isacco Desideri, Mauro Loi, Monica Mangoni, Mariangela Sottili, Livia Marrazzo, Cinzia Talamonti, Daniela Greto, Stefania Pallotta, Lorenzo Livi
Published 2018-02-01

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Admin...

by Tanja Eichkorn, Tanja Eichkorn, Farastuk Bozorgmehr, Farastuk Bozorgmehr, Sebastian Regnery, Sebastian Regnery, Lisa A. Dinges, Lisa A. Dinges, Andreas Kudak, Andreas Kudak, Andreas Kudak, Nina Bougatf, Nina Bougatf, Nina Bougatf, Nina Bougatf, Dorothea Weber, Petros Christopoulos, Petros Christopoulos, Petros Christopoulos, Thomas Muley, Thomas Muley, Thomas Muley, Sonja Kobinger, Sonja Kobinger, Sonja Kobinger, Laila König, Laila König, Juliane Hörner-Rieber, Juliane Hörner-Rieber, Juliane Hörner-Rieber, Sebastian Adeberg, Sebastian Adeberg, Claus Peter Heussel, Claus Peter Heussel, Claus Peter Heussel, Claus Peter Heussel, Michael Thomas, Michael Thomas, Michael Thomas, Jürgen Debus, Jürgen Debus, Jürgen Debus, Jürgen Debus, Jürgen Debus, Rami A. El Shafie, Rami A. El Shafie
Published 2020-12-01

Lichen planus pemphigoides versus bullous pemphigoid: A diagnostic dilemma of cutaneous adverse event in a case of nonsmall cell lung cancer treated with durvalumab

by Ketki Shekhar Bhoite, Sunanda Arun Mahajan, Shefali A Saini
Published 2021-01-01

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

by Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy
Published 2020-07-01

Management of the Adverse Effects of Immune Checkpoint Inhibitors

by Manuel Morgado, Ana Plácido, Sandra Morgado, Fátima Roque
Published 2020-10-01

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

by Houda Bahig, Francine Aubin, John Stagg, Olguta Gologan, Olivier Ballivy, Eric Bissada, Felix-Phuc Nguyen-Tan, Denis Soulières, Louis Guertin, Edith Filion, Apostolos Christopoulos, Louise Lambert, Mustapha Tehfe, Tareck Ayad, Danielle Charpentier, Rahima Jamal, Philip Wong
Published 2019-01-01

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report

by Romain Varnier, Thibaut Garrivier, Emilie Hafliger, Aymeric Favre, Clélia Coutzac, Clément Spire, Pauline Rochefort, Matthieu Sarabi, Françoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Pamela Funk-Debleds, Charles Mastier, Adrien Buisson, David Pérol, Oliver Trédan, Jean-Yves Blay, Jean-Marc Phelip, Christelle de la Fouchardiere
Published 2021-09-01